Shots:

• The P-II (REFINE) trial evaluates navitoclax + ruxolitinib in patients with myelofibrosis who had progressed on or had a suboptimal response to 12wks. of ruxolitinib monothx.
• In an exploratory analysis of 32 patients, 12 (38%) had a ≥ 1-grade improvement, 26 were evaluable for driver gene VAF reduction & 6 (23%) achieved a ≥20% reduction @24wk., 5 achieved BMF & VAF responses, m-OS was not reached for patients who had a ≥ 1-grade improvement in BMF or ≥20% driver gene VAF reduction over 28.5mos. who did not experience an improvement
• Additionally, 100% experienced 1 AEs & 15 (44%) SAE, no SAEs of bleeding & thrombocytopenia was manageable & reversible with dose reduction of navitoclax & ruxolitinib

Ref: PR Newswire | Image: AbbVie